Xu Kunyong, Chan Tommy C Y, Vajpayee Rasik B, Jhanji Vishal
From the *Department of Ophthalmology, Queen's University, Kingston, Canada; †Department of Ophthalmology, Hotel Dieu and Kingston General Hospitals, Kingston, Canada; ‡Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong; §Hong Kong Eye Hospital, Hong Kong; ¶Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia; ∥Vision Eye Institute, Royal Victorian Eye and Ear Hospital, North West Academic Centre University of Melbourne, Melbourne, Australia; and **Department of Ophthalmology, Prince of Wales Hospital, Hong Kong.
Asia Pac J Ophthalmol (Phila). 2015 Sep-Oct;4(5):300-6. doi: 10.1097/APO.0000000000000145.
Corneal collagen cross-linking (CXL) has been shown to slow down or stop the progression of keratoconus. In addition, CXL has been applied in cases of corneal ectasia. Recent reports of the use of CXL in cases of infectious keratitis have generated further interest in this treatment modality. This review discusses the principle, clinical uses, and complications associated with CXL.
角膜胶原交联（CXL）已被证明可减缓或阻止圆锥角膜的进展。此外，CXL已应用于角膜扩张症病例。近期关于在感染性角膜炎病例中使用CXL的报道引发了对这种治疗方式的更多关注。本综述讨论了与CXL相关的原理、临床应用及并发症。
Zotero 插件